Vyvanse™ Safety, Tolerability and Dosing Information
Vyvanse adverse event profile[2]
- Majority of adverse events in study were generally mild to moderate in severity and incidence decreased over time[1] (Table 6-1)
| Adverse Event | Vyvanse (n=218) | Placebo (n=72) |
| Abdominal pain upper | 12% | 6% |
| Dry mouth | 5% | 0% |
| Nausea | 6% | 3% |
| Vomiting | 9% | 4% |
| Pyrexia | 2% | 1% |
| Weight decreased | 9% | 1% |
| Decreased appetite | 39% | 4% |
| Dizziness | 5% | 0% |
| Headache | 12% | 10% |
| Somnolence | 2% | 1% |
| Affect lability | 3% | 0% |
| Initial insomnia | 4% | 0% |
| Insomnia | 19% | 3% |
| Irritability | 10% | 0% |
| Tic | 2% | 0% |
| Rash | 3% | 0% |
Table 6-1. Vyvanse Adverse Events Reported by 2% or More
of Patients (N=290). This table includes only those events for which the incidence
in patients taking Vyvanse is greater than the incidence in patients taking
placebo.
3 dosage strengths in 20-mg increments (Figure 6-1)[2]
Figure 6-1. Vyvanse offers 3 dosing options.
- For pediatric patients either starting treatment or switching from another medication, the recommended dose is 30 mg once daily in the morning[2]
- At weekly intervals, dose may be titrated in 20-mg increments[2]
- The maximum recommended dose is 70 mg/day[2]
- Capsules may be taken whole, or may be opened and the entire contents dissolved in a glass of water and consumed immediately[2]
